Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
A minimalist representation of a pill and a molecule in flat design.

Jun 19, 2026

Pharma-Bio Association Holds First AI Drug Discovery Advisory Committee Meeting

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association recently convened its inaugural AI Drug Discovery Advisory Committee meeting, marking a significant step in integrating artificial intelligence into drug development.Held at the Parnas Hotel in Seoul, the meeting focused on enhancing educational initiatives and promoting AI-driven drug development. Key discussions included the introduction of a comprehensive training program aimed at equipping professionals with practical skills i
A peptide sample in a lab setting

Jun 18, 2026

LG AI Research and D&D Pharmatech Join Forces to Accelerate AI-Powered Oral Peptide Drug Discovery

LG AI Research has partnered with D&D Pharmatech to push the boundaries of oral peptide drug development using AI technology.The collaboration aims to revolutionize drug discovery by integrating LG's advanced AI capabilities with D&D's expertise in peptide development. This partnership was formalized at a signing ceremony in Seoul, attended by executives from both companies. Woohyung Lim from LG AI Research emphasized that this initiative is not just about technology adoption; it represents a st
A close-up of a cell culture dish with RNA strands in a laboratory setting.

Jun 18, 2026

Portal Biotechnologies Raises $9 Million To Expand Cell Engineering Platform

Portal Biotechnologies has successfully secured $9 million in an oversubscribed financing round aimed at enhancing its cell engineering and drug discovery platform.The funding, led by NFX and supported by existing investors like IA Ventures and Pear VC, will facilitate the commercial scaling of Portal's innovative platform. This technology addresses a critical challenge in biology: the efficient delivery of complex molecules into cells without compromising their function. Portal's mechanoporatio
A syringe and vial in a dimly lit lab setting

Jun 18, 2026

Insilico Medicine to showcase AI-driven drug breakthroughs at BIO 2026 International Convention

Insilico Medicine is set to present its advancements in AI-driven drug discovery at the upcoming BIO 2026 International Convention in San Diego, scheduled for June 22-25. The company aims to engage with biopharma partners and researchers, showcasing its Pharma.AI platform alongside its R&D pipeline.Dr. Alex Zhavoronkov, the company's founder and CEO, will deliver four significant presentations during the event. These will cover a range of topics, including the impact of AI on drug development, i
A molecular model on a lab bench with test tubes

Jun 18, 2026

AI Meets CRO: How Charles River and Lilly Are Rewriting Drug Discovery

The collaboration between Charles River Laboratories and Eli Lilly's TuneLab signifies a transformative advancement in drug discovery, merging AI capabilities with empirical testing to enhance innovation while mitigating costs and ethical issues.This partnership is designed to revolutionize the drug development process by integrating Charles River's extensive experience in nonclinical testing with TuneLab's advanced AI models. The goal is to streamline the transition from initial molecular conce
A vial of liquid and a research notebook in a dimly lit lab.

Jun 18, 2026

LG Chem announced on the 18th that it has signed a joint research and licensing option contract with..

LG Chem has entered a strategic partnership with Lab-Genius Therapeutics to advance cancer drug development using AI technologies.On the 18th, LG Chem announced a joint research and licensing option agreement with the British biotech firm Lab-Genius Therapeutics. This collaboration aims to discover new drug candidates specifically for multi-antibody anticancer therapies. As part of the agreement, LG Chem will provide an initial payment along with research funding to Lab-Genius, which will levera
A pill on a clinical trial table with a participant in the background.

Jun 17, 2026

Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics

Insilico Medicine has marked a significant milestone by completing first-in-human dosing of its AI-generated NLRP3 inhibitor, ISM8969, in collaboration with Hygtia Therapeutics. This Phase I clinical trial aims to evaluate the safety and pharmacokinetics of ISM8969, which targets chronic neuroinflammation linked to CNS disorders like Parkinson's disease.The Phase I study is being conducted in Australia and will involve 100 participants, including healthy individuals and those at risk of cardiova
A minimalist representation of a drug molecule for anticancer research.

Jun 17, 2026

JW Pharma selected for government-backed AI anticancer drug discovery project

JW Pharmaceutical has been chosen as the lead institution for a government-supported initiative aimed at enhancing anticancer drug discovery through AI technology.The Korean Ministry of Health and Welfare has launched the "Structure-Based AI Drug Discovery Support" project, allocating 2.2 billion won (approximately $1.45 million) to JW Pharmaceutical and its research partner, C&C Research Laboratories. This funding will be utilized over the next three years to identify new anticancer drug candid
A small molecule in a petri dish on a lab bench

Jun 16, 2026

EVGN: AI-driven platform accelerates multi-parameter small molecule discovery for pharma and ag-chem

Evogene Ltd. has unveiled a proprietary AI platform designed to enhance the discovery of small molecules for pharmaceutical and agricultural chemical applications. This innovative technology focuses on optimizing multiple parameters, significantly expediting the discovery process.The company emphasizes the importance of strategic partnerships and collaborations, which are instrumental in developing a diverse pipeline of products. This approach not only strengthens their position in the pharmaceu
Minimalist illustration of a neuron with a receptor

Jun 16, 2026

AI: Breaking barriers in CNS research

Advancements in artificial intelligence are revolutionizing drug design, particularly in central nervous system (CNS) research, according to David Del Bourgo, CEO of WhiteLab Genomics.Del Bourgo emphasizes a shift from traditional trial-and-error methods in drug development to a more engineered approach. By utilizing AI, WhiteLab identifies specific receptors unique to target cell types, ensuring these receptors are present on the cell surface. Their proprietary mapping technology leverages huma
A vial of RNAi drug compound on a lab table with a research notebook.

Jun 16, 2026

Does Alnylam’s Generative AI Pact With Inceptive Nucleics Redraw The R&D Bull Case For ALNY?

Alnylam Pharmaceuticals has entered a significant collaboration with Inceptive Nucleics, valued at up to $2 billion, to enhance its RNAi drug discovery processes using generative AI. This partnership includes an upfront investment of $30 million and access to advanced AI talent, potentially improving research productivity and expanding Alnylam's pipeline.The collaboration is poised to impact Alnylam's investment narrative, particularly concerning its R&D productivity and the breadth of its drug
A protein sample on a lab bench in a dimly lit laboratory

Jun 16, 2026

Merck Taps Protillion for AI Protein Design

Merck has entered into a significant collaboration with Protillion Biosciences to enhance its capabilities in AI-driven drug discovery.The partnership aims to leverage Protillion's advanced Prot-MaP technology, which is designed for large-scale data generation to facilitate protein design. This technology provides extensive, timely training datasets for AI applications, allowing for the analysis of vast protein libraries with high efficiency. By addressing common challenges such as model overfit